High Tregs and Systemic IL-10 Expressions Linked to the Absence of Sheath Antibodies in Lymphatic Filariasis: Implications on the Persistence of Residual Infection

Overview

Journal Immunol Res

Specialty Allergy & Immunology

Date 2021 Jan 30

PMID 33515426

Citations 1

Authors

Madhusmita Bal

Manoranjan Ranjit

Hemanta K Khuntia

Ashok K Satapathy

K Gopinath Achary

Bhagirathi Dwibedi

Sanghamitra Pati

Affiliations

Soon will be listed here.

Abstract

The persistence of residual infection is one of the major factors in failure of the Global Programme to Eliminate Lymphatic Filariasis (GPELF). The present study aims to explore the status of sheath antibody and regulatory T cells (Tregs) known to play key roles in clearance of parasite and patent filarial infection, in individuals with residual infection after MDA. A total of 61 microfilaremic (Mf) individuals were followed up after at least 6 rounds of MDA. Infection status of subjects was assessed through the detection of Mf and circulating filarial antigen (CFA). Antibodies to Mf sheath were determined by immuno-peroxidase assay (IPA). The expression of Tregs was measured by a flow cytometer. IL-10 and IFN-γ were evaluated using the commercially available ELISA kit. The sheath antibody was present in subjects who have cleared both Mf and CFA and absent in individuals who were found to be Mf /CFA positive. Further individuals carrying infection have significantly high levels of Tregs and IL-10. A positive correlation was observed between Tregs, IL-10, and CFA in infected individuals. In contrast, a negative correlation was observed between IFN-γ and IL-10 in both infected and uninfected subjects. Our study reveals that the absence of a sheath antibody and a high level of Tregs and IL-10 are the hallmarks of the persistence of residual filarial infection.

Citing Articles

Reduced Type 2 Innate Lymphocyte Cell Frequencies in Patent -Infected Individuals.

Tamadaho R, Osei-Mensah J, Arndts K, Debrah L, Debrah A, Layland L Pathogens. 2023; 12(5).

PMID: 37242335 PMC: 10223000. DOI: 10.3390/pathogens12050665.

References

Achary K, Mandal N, Mishra S, Mishra R, Sarangi S, Satapathy A . In utero sensitization modulates IgG isotype, IFN-γ and IL-10 responses of neonates in bancroftian filariasis. Parasite Immunol. 2014; 36(10):485-93. DOI: 10.1111/pim.12121. View

Babu S, Nutman T . Immunology of lymphatic filariasis. Parasite Immunol. 2013; 36(8):338-46. PMC: 3990654. DOI: 10.1111/pim.12081. View

Babu S, Ganley L, Klei T, Shultz L, Rajan T . Role of gamma interferon and interleukin-4 in host defense against the human filarial parasite Brugia malayi. Infect Immun. 2000; 68(5):3034-5. PMC: 97525. DOI: 10.1128/IAI.68.5.3034-3035.2000. View

Bal M, Ranjit M, Achary K, Satapathy A . Maternal Filarial Infection Influences the Development of Regulatory T Cells in Children from Infancy to Early Childhood. PLoS Negl Trop Dis. 2016; 10(11):e0005144. PMC: 5115651. DOI: 10.1371/journal.pntd.0005144. View

de Souza D, Ansumana R, Sessay S, Conteh A, Koudou B, Rebollo M . The impact of residual infections on Anopheles-transmitted Wuchereria bancrofti after multiple rounds of mass drug administration. Parasit Vectors. 2015; 8:488. PMC: 4581406. DOI: 10.1186/s13071-015-1091-z. View

Gillan V, Devaney E . Regulatory T cells modulate Th2 responses induced by Brugia pahangi third-stage larvae. Infect Immun. 2005; 73(7):4034-42. PMC: 1168597. DOI: 10.1128/IAI.73.7.4034-4042.2005. View

Kalimuthu M, Sunish I, Nagaraj J, Munirathinam A, Kumar V, Arunachalam N . Residual microfilaraemia in rural pockets of South India after five rounds of DEC plus albendazole administration as part of the LF elimination campaign. J Vector Borne Dis. 2015; 52(2):182-4. View

Kar S, Dwibedi B, Kerketa A, Maharana A, Panda S, Mohanty P . A randomized controlled trial of increased dose and frequency of albendazole with standard dose DEC for treatment of Wuchereria bancrofti microfilaremics in Odisha, India. PLoS Negl Trop Dis. 2015; 9(3):e0003583. PMC: 4363665. DOI: 10.1371/journal.pntd.0003583. View

King C, Mahanty S, Kumaraswami V, Abrams J, Regunathan J, Jayaraman K . Cytokine control of parasite-specific anergy in human lymphatic filariasis. Preferential induction of a regulatory T helper type 2 lymphocyte subset. J Clin Invest. 1993; 92(4):1667-73. PMC: 288325. DOI: 10.1172/JCI116752. View

10.

Lau C, Sheridan S, Ryan S, Roineau M, Andreosso A, Fuimaono S . Detecting and confirming residual hotspots of lymphatic filariasis transmission in American Samoa 8 years after stopping mass drug administration. PLoS Negl Trop Dis. 2017; 11(9):e0005914. PMC: 5619835. DOI: 10.1371/journal.pntd.0005914. View

11.

Mahanty S, Mollis S, Ravichandran M, Abrams J, Kumaraswami V, Jayaraman K . High levels of spontaneous and parasite antigen-driven interleukin-10 production are associated with antigen-specific hyporesponsiveness in human lymphatic filariasis. J Infect Dis. 1996; 173(3):769-73. DOI: 10.1093/infdis/173.3.769. View

12.

Metenou S, Nutman T . Regulatory T cell subsets in filarial infection and their function. Front Immunol. 2013; 4:305. PMC: 3786323. DOI: 10.3389/fimmu.2013.00305. View

13.

Metenou S, Dembele B, Konate S, Dolo H, Coulibaly S, Coulibaly Y . At homeostasis filarial infections have expanded adaptive T regulatory but not classical Th2 cells. J Immunol. 2010; 184(9):5375-82. PMC: 3407820. DOI: 10.4049/jimmunol.0904067. View

14.

Molyneux D . Advancing toward the Elimination of Lymphatic Filariasis. N Engl J Med. 2018; 379(19):1871-1872. DOI: 10.1056/NEJMe1811455. View

15.

Ramaiah K, Ottesen E . Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease. PLoS Negl Trop Dis. 2014; 8(11):e3319. PMC: 4239120. DOI: 10.1371/journal.pntd.0003319. View

16.

Ravindran B, Satapathy A, Sahoo P, Mohanty M . Protective immunity in human lymphatic filariasis: problems and prospects. Med Microbiol Immunol. 2003; 192(1):41-6. DOI: 10.1007/s00430-002-0157-7. View

17.

Ravindran B, Satapathy A, Sahoo P . Bancroftian filariasis-differential reactivity of anti-sheath antibodies in microfilariae carriers. Parasite Immunol. 1994; 16(6):321-3. DOI: 10.1111/j.1365-3024.1994.tb00355.x. View

18.

Rebollo M, Bockarie M . Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame. Expert Rev Anti Infect Ther. 2013; 11(7):723-31. DOI: 10.1586/14787210.2013.811841. View

19.

Sheel M, Sheridan S, Gass K, Won K, Fuimaono S, Kirk M . Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016. PLoS Negl Trop Dis. 2018; 12(7):e0006583. PMC: 6062125. DOI: 10.1371/journal.pntd.0006583. View

20.

Stolk W, Ten Bosch Q, de Vlas S, Fischer P, Weil G, Goldman A . Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis. PLoS Negl Trop Dis. 2013; 7(1):e1984. PMC: 3536806. DOI: 10.1371/journal.pntd.0001984. View